Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 7, 2009, Pages 757-766

  Ng, S C ^a   Plamondon, S ^a   Gupta, A ^b   Burling, D ^b   Kamm, M A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL ARTICLE; COLON CROHN DISEASE; CONTROLLED STUDY; CROHN PERINEAL FISTULA; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERINEUM; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG EVALUATION; EPIDEMIOLOGIC METHODS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERINEUM; QUALITY OF LIFE; RECTAL FISTULA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 69949132409     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04088.x     Document Type: Article

References (35)

1. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001 135 : 906 918.
2. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004 116 (Suppl 7A 44S 9S.
3. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003 98 : 1064 1072. (Pubitemid 36733768)
4. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975 68 : 627 635.
5. Lapidus A, Bernell O, Hellers G, Lofberg R. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998 114 : 1151 1160.
6. Bell SJ, Williams AB, Wiesel P, Wilkinson K, Cohen RC, Kamm MA. The clinical course of fistulating Crohn's disease. Aliment Pharmacol Ther 2003 17 : 1145 1151.
7. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002 16 : 1603 1609.
8. Gazzard BG. The quality of life in Crohn's disease. Gut 1987 28 : 378 381.
9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.
10. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009 58 : 940 948.
11. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003 98 : 2232 2238.
12. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008 103 : 3132 3141.
13. Colombel JF, Loftus EV, Feagan BG. Impact of Adalimumab (Humira) on patient-reported outcomes among patients with fistulising Crohn's disease. Am J Gastroenterol 2007 102, S457(#921).
14. Ng SC, Plamondon S, Swatton A, Gupta A, CJ Vaizey, Kamm MA. Top-down" anti-tumour necrosis factor therapy for Crohn's fistulas guided by prospective magnetic resonance imaging to monitor deep tissue healing. Gut 2008 (suppl 2 P0777.
15. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995 20 : 27 32.
16. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 444.
17. Best WR, Becktel JM. The Crohn's disease activity index as a clinical instrument. In : Pena A, Weterman IT, Booth CC, Strober W, eds. Recent Advances in Crohn's Disease. The Hague : Martinus Nijhoff, 1981 : 7 12.
18. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980 1 : 514.
19. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994 106 : 287 296.
20. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999 28 : S23 7.
21. Halligan S. Imaging fistula-in-ano. Clin Radiol 1998 53 : 85 95.
22. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976 63 : 1 12.
23. Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003 98 : 332 339.
24. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989 96 : 804 810. (Pubitemid 19057603)
25. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002 8 : 237 243.
26. Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008 23 : 289 296.
27. van Balkom BP, Schoon EJ, Stockbrugger RW, et al. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther 2002 16 : 1101 1107.
28. Cadahia V, Garcia-Carbonero A, Vivas S, et al. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice. Rev Esp Enferm Dig 2004 96 : 369 374.
29. Loftus EV, Feagan BG, Colombel JF, et al. Impact of Adalimumab (Humira) on patient-reported outcomes. Am J Gastroenterol 2007 102 (suppl 2 S456[#920].
30. Colombel JF, Sandborn WJ, Rutgeerts Peal. Continuous vs induction only/reinitiated adalimumab maintenance therapy yields optimal results for moderate to severe Crohn's disease: subanalysis of CHARM. Am J Gastroenterol 2007 102 : S457[#922].
31. Schwartz DA, Colombel J-F, Rutgeerts P, et al. Sustained improvement in quality of life for patients with fistulising crohn's disease treated with adalimumab: 3 year data from CHARM. Gastroenterology, 2009 136 (Suppl 1 S1063.
32. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995 123 : 132 142.
33. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001 13 : 567 572.
34. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992 305 : 160 164.
35. Allan A, Linares L, Spooner HA, exander-Williams J. Clinical index to quantitate symptoms of perianal Crohn's disease. Dis Colon Rectum 1992 35 : 656 661.